Full Press Release Details
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034)
PRIMA BIOMED S CEO TO
PRESENT AT 11th ANNUAL COMMERCIAL TRANSLATION OF REGENERATIVE MEDICINE MEETING
AUSTRALIA Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company ) today announced that its Chief Executive Officer, Matthew Lehman, will present at the 11th Annual Commercial Translation of Regenerative Medicine meeting in London on November 25, 2013 at 1:55pm local time.
Mr. Lehman will deliver a presentation entitled Immunocellular Cell Therapy Approach to Clinical Success and discuss CVac clinical
trials as a case study.
Prima BioMed is a globally active leader in the development of personalized immunocellular therapeutic products for the treatment of cancer. Prima is
dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Prima s lead product is CVac , an autologous dendritic cell-based product currently in
For further information please contact:
Ms. Jessica Brown, Prima BioMed
+1 (919) 710-9061; jessica.brown@primabiomed.com.au
Australia Investor/Media:
Mr. James Moses, Mandate
+61 (0) 420 991 574; james@mandatecorporate.com.au
Europe Investor/Media:
+49 (0) 69 905505-52; amuehlhaus@edicto.de
Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000
Phone: +61 2 9276 1224 Fax: +61 2 9276 1284